Hematopoiesis

Li+ also affects the response of lymphocytes to some mitogens. In vitro, Li+ has little effect on lymphocytes in mice, rats, and humans however, in hamsters the stimulation of lymphocytes is enhanced by the presence of Li+ [205], In patients with immunodeficiency due to excess suppresser T-cell activity, Li+ is effective in inactivating this excess in vitro and, subsequently, the number of (3-lymphocytes increases however in vivo the immunodeficiency is unaffected [206]. There is no apparent consistent, Li+-induced effect on the levels of the immunoglobulins. 

Recently in a study of long-term Li+ patients, the levels of neutrophils, helper T-cells, -lymphocytes, and NK cells were all significantly higher than normal, indicating that these, generally favorable, quantitative changes in leucocyte populations persist with Li+ therapy [207]. 

The effects of Li+ upon hematopoiesis have been proposed to be due to two different systems modification of the activity of the membrane Na+/K+-ATPase, and the inhibition of adenylate cyclase. Monovalent cation flux, in particular Na+ transport, is known to influence the differentiation and proliferation of hematopoietic stem cells. For instance, ouabain, an effective inhibitor of the membrane Na+/K+-ATPase, blocks the proliferation of lymphocytes and has been shown to attenuate the Li+-induced proliferation of granulocyte precursors [208]. Conversely, Li+ can reverse the actions of amphotericin and monensin, which mediate Na+ transport and which inhibit CFU-GM, CFU-E, and CFU-MK colony formation in the absence of Li+ [209]. Therefore, the influence of Li+ upon normal physiological cation transport—for example, its influence upon Na+/K+-ATPase activity—may be partly responsible for the observed interference in hematopoiesis. 

The overall effect of Li+ on the hematopoietic system is of stimulation of the immune system. Not surprisingly then, Li+ is reported to exacerbate the activity of a number of autoimmune diseases, such as psoriasis [212] and rheumatoid arthritis [213], and to result in the production of autoantibodies in some patients [214]. However, there is no evidence that Li+ s stimulation of the immune system leads to any reduction in the occurrence of viral or bacterial infections in patients on Li+ therapy. 

AIDS is associated with aberrant lymphocyte production and it has been proposed that Li+ may have a potential role in reversing this. Additionally, 3 -azido-3 deoxythymidine (AZT, zidovudine), an effective inhibitor of viral reverse transcriptase that reduces mortality in AIDS patients, induces hematopoietic suppression in patients resulting in anemia, neutropenia, and overall bone-marrow failure [220]. In murine AIDS, the coadministration of Li+ effectively moderates this toxicity of AZT in vivo [221,222]. There are several case reports where Li+ has been administered to help reduce the hematopoietic suppression in HIV-infected patients taking AZT (for example, see ref. 223). To date, the use of Li+ has been limited to a few weeks of treatment, and varying degrees of success have been achieved nevertheless the outlook in this field is quite hopeful. 

Downstream astakine 1, another protein named crustacean hematopoietic factor (CHF) is critical for the survival of the hemocytes and its removal 

---

Deficiency. Macrocytic anemia, megaloblastic anemia, and neurological symptoms characterize vitamin B 2 deficiency. Alterations in hematopoiesis occur because of the high requirement for vitamin B 2 for normal DNA repHcation necessary to sustain the rapid turnover of the erythrocytes. Abnormal DNA repHcation secondary to vitamin B 2 deficiency produces a defect in the nuclear maturational process of committed hematopoietic stem cells. As a result, the erythrocytes are either morphologically abnormal or die during development. 

SCF Due to splice variants there are soluble and membrane forms of SCF KIT/SCFR Hematopoiesis, gametogenesis, and me-lanogenesis... 

Hematopoietic (blood) cells transport oxygen and carbon dioxide, contribute to host immunity, and facilitate blood clotting [1], A complex, interrelated, and multistep process, called hematopoiesis, controls the production as well as the development of specific marrow cells from immature precursor cells to functional mature blood cells. This well-regulated process also allows for replacement of cells lost through daily physiologic activities. The proliferation of precursor cells, the maturation of these into mature cells, and the survival of hematopoietic cells require the presence of specific growth factors. 

Hematopoietic Growth Factors. Figure 1 Schema of hematopoiesis, including some of the growth factors that influence the production of blood cells. 

Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90 1345-1364... 

Helicobacter Pylori Helix Bundle Helix-loop-helix Motif Helper T Cells Hemangioblast Hematopoiesis... 

Shigematsu H, Ozawa H, Tenen TG, Austen KF. Akashi K Developmental checkpoints of the baso-phil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci USA 2005 102 18105-18110. 14... 

Jenkins M, Hanley MB, Moreno MB, Wieder E, McCune JM (1998) Human immunodeficiency irus-l infection interrupts thymopoiesis and multilineage hematopoiesis in vivo. Blood 91(8) 2672-2678 Jones KA, Peterlin BM (1994) Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 63 717-743... 

Cancer patients also may have concurrent iron deficiency secondary to erythropoietin use ( functional iron deficiency) or to cancer. Therefore, it is imperative that these patients have iron studies done to assess adequate iron stores needed to drive hematopoiesis. If the patient is determined to have sub-optimal iron stores or is iron deficient, then replacement either orally or intravenously may be necessary, in addition to the use of erythropoietin products. The use of iron in these patients is the same as discussed previously under Iron-Deficiency Anemia. ... 

O The acute leukemias are hematologic malignancies of bone marrow precursors characterized by excessive production of immature hematopoietic cells. This proliferation results in a large number of immature cells (blasts) appearing in the peripheral blood and bone marrow causing failure of normal hematopoiesis. 

O The acute leukemias are diseases of bone marrow resulting from aberrant proliferation of hematopoietic precursors. The hallmark of these malignancies is the leukemic blast cell, a visibly immature and abnormal cell in the peripheral blood that often replaces the bone marrow and interferes with normal hematopoiesis. These blast cells proliferate in the marrow and inhibit normal cellular elements, resulting in anemia, neutropenia, and thrombocytopenia. Leukemia also may infiltrate other organs, including the liver, spleen, bone, skin, lymph nodes, and central nervous system (CNS). Virtually anywhere there is blood flow, the potential for extramedullary (outside the bone marrow) leukemia exists. 

Hematopoiesis is defined as the development and maturation of blood cells and their precursors. In utero, hematopoiesis may occur in the liver, spleen, and bone marrow. However, after birth, it occurs exclusively in the bone marrow. All blood cells are generated from a common hematopoietic precursor, or stem cell. These stem cells are self-renewing and pluripotent and thus are able to commit to any one of the different lines of maturation that give rise to platelet-producing megakaryocytes, lymphoid, erythroid, and myeloid cells. The myeloid cell line produces monocytes, basophils, neutrophils, and eosinophils, whereas the lymphoid stem cell differentiates to form circulating B and T lymphocytes. In contrast to the ordered development of normal cells, the development of leukemia seems to represent an arrest in differentiation at an early phase in the continuum of stem cell to mature cell.1... 

Flow cytometric evaluation of bone marrow and peripheral blood to characterize the type of leukemia, as well as to detect specific chromosomal rearrangements. The bone marrow at diagnosis usually is hypercellular, with normal hematopoiesis being replaced by leukemic blasts. The presence of greater than 20% blasts in the bone marrow is diagnostic for AML. 

After completion of induction and restoration of normal hematopoiesis, patients begin intensification (consolidation). The goal of intensification is to administer dose-intensive chemotherapy in an effort to further reduce the burden of... 

In HSCT, very high doses of chemotherapy with or without total-body radiation (TBI) are given in an attempt to potentiate leukemia cell kill. Hematopoiesis is restored by the infusion of stem cells harvested from an HLA-compatible donor, thereby rescuing the patient from the consequences of total aplasia.13 It is the most effective antileukemic therapy currently available. 

Develop a plan for monitoring and managing engraftment of hematopoiesis. 

A myeloablative preparative regimen involves the administration of sublethal doses of chemotherapy to the recipient. The recipient will not regain his or her own hematopoiesis (i.e., graft failure or graft rejection) and will... 

Engraftment is the reestablishment of functional hematopoiesis. It is commonly defined as the point at which a patient can maintain a sustained absolute neutrophil count (ANC) of greater than 500 cells/mm3 (0.5 x 109/L) and a sustained platelet count of greater 20,000/mm3 (20 x 109/L) lasting for 3 or more consecutive days without transfusions. 

A delicate balance between host and donor effector cells is necessary, and residual host-versus-graft effects may lead to graft failure, which is also known as graft rejection. Graft failure is defined as the lack of functional hematopoiesis after HCT and can occur early (i.e., lack of initial hematopoietic... 

Beyond roles of chemokine receptors in hematopoiesis and innate immunity, roles for chemokines in adaptive immunity emerged. Moreover, other nonleukocyte migration properties of chemokine receptors have been identified. These include roles in the biology of endothelial cells (Chapter 15), cancer (Chapter 16), smooth muscle (Chapter 11), fibroblasts (Chapter 14), stem cells (Chapter 8), and all cell types associated with nervous system tissues (Chapter 17). In many instances, broad functional overlap is evident as chemokines can direct the migration of these cells just as they do with leukocytes. In certain instances, the ability of chemokines to retain cell populations within a specific microenvironment is as important as their migration-promoting properties. However, it is also clear that migration and retention are not the sole end points. 

Gao J-L, Wynn TA, Chang Y, et al. Imparted host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med 1997 185 1959-1968. 

Chemokines in Trafficking of Hematopoietic Stem and Progenitor Cells and Hematopoiesis... 

Key Words Stem cells chemokines hematopoiesis chemotaxis T cells B cells. 

---